Status:
ACTIVE_NOT_RECRUITING
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
Lead Sponsor:
Sanofi
Conditions:
Dermatitis Atopic
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently...
Detailed Description
The study duration will be up to 36 weeks
Eligibility Criteria
Inclusion
- Participants must be 18 years of age (when signing informed consent form)
- Diagnosis of AD for at least 1 year (defined by the American Academy of Dermatology Consensus Criteria)
- Documented history (within 6 months before screening) of either inadequate response or inadvisability to topical treatments
- Validated Investigator Global Assessment scale for atopic dermatitis (vIGA-AD) of 3 or 4 at baseline visit
- Eczema area and severity index (EASI) score of 12 or higher at baseline
- AD involvement of 10% or more of body surface area (BSA) at baseline
- Able and willing to comply with requested study visits and procedures
- Body weight ≥40 kg and ≤150 kg
Exclusion
- Skin co-morbidity that would adversely affect the ability to undertake AD assessments
- Receipt of any vaccine (expect influenza and COVID-19 vaccines) within 3 months prior to screening
- Receipt of any pneumococcal vaccine within approximate timeframe of 5 years prior to screening
- Prior receipt of two or more doses of Pneumovax 23 at any time
- Receipt of any tetanus-, diphtheria-, or pertussis-containing vaccine within approximate timeframe of 5 years prior to screening
- Participants for whom administration of the pneumococcal vaccine provided in this study is contraindicated or medically inadvisable, according to local label of the vaccine
- Participants for whom administration of the tetanus, diphtheria, and pertussis vaccine provided in this study is contraindicated or medically inadvisable, according to local label of the vaccine
- Having received any of the specified therapy within the specified timeframe(s) prior to the baseline visit
- Known history of or suspected significant current immunosuppression
- Any malignancies or history of malignancies prior to baseline (excluding non-melanoma skin cancer excised and cured \>5 years prior to baseline)
- History of solid organ or stem cell transplant
- Any active or chronic infection including helminthic infection requiring systemic treatment within 2 weeks prior baseline
- Positive for human immunodeficiency virus (HIV), Hepatitis B or hepatitis C at screening visit
- Participants with active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, or who are at high risk of contracting TB
- The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Key Trial Info
Start Date :
October 6 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
224 Patients enrolled
Trial Details
Trial ID
NCT06015308
Start Date
October 6 2023
End Date
December 31 2025
Last Update
October 24 2025
Active Locations (57)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Center of Alabama - Homewood- Site Number : 8401101
Birmingham, Alabama, United States, 35209
2
Center for Dermatology and Plastic Surgery- Site Number : 8401119
Scottsdale, Arizona, United States, 85260
3
Orange County Clinical Trials- Site Number : 8401271
Anaheim, California, United States, 92801
4
First OC Dermatology- Site Number : 8401025
Fountain Valley, California, United States, 92708